News

An artificial intelligence (AI) algorithm predicts outcomes in patients diagnosed with COVID-19.

New study provides deep insights into the COVID-19 pandemic.

A recently created therapy for the influenza virus may help aid in the fight against COVID-19.

The guidelines were recently updated to reflect new information on COVID-19 treatment and management.

The influenza therapy is expanded to include people who have been exposed to the flu.

Accuracy of test may be influenced by size of population to be screened and prevalence of COVID-19 within that population.

New details of SARS-CoV-2 have been obtained using 3D modeling, providing crucial insights into the disease.

National Institute of Allergy and Infectious Disease (NIAID) has selected Metabolon to participate in a study on this subject.

Data shows their AZD1222 vaccine met its endpoint and they are preparing regulatory submission for conditional or early approval.

A research team developed an algorithm review estimating not only hospital admissions, but also mortality outcomes in adults with COVID-19.

Children who were exposed to antibiotics before age 2 had a greater risk of childhood health conditions like asthma, celiac disease, obesity and ADHD, a new study in Mayo Clinic Proceedings found.

Study finds that a century-old tuberculosis vaccine could be used in the treatment and prevention of COVID-19.

The third EUA granted to an investigational COVID-19 therapy regimen is indicated for preventing progression from mild, to severe symptoms.

Immunologists have discovered possible treatments for COVID-19 using existing therapies.

The Aptima HIV-1 Quant Dx assay is the first in the US to be able to make such a claim.

This guidance comes less than 24 hours after FDA grants an EUA for its use combined with baricitinib.

The measles-mumps-rubella (MMR) vaccine could potentially aid in the protection against COVID-19.

Two recent studies conducted by Kansas State University researchers resulted in important findings related to the current COVID-19 pandemic.

Here is what you need to know about BNT162b2, possibly the first vaccine regulated for COVID-19 prevention.

This EUA is for the treatment of hospitalized patients who require oxygen.

Researchers have identified the Ski complex as a promising target for antiviral drugs in the fight against coronaviruses.

Patients testing positive for SARS-CoV-2 after recovery and negative tests are re-examined to determine if they are reinfected and/or infectious.

Gilead has announced that its investigational long-acting HIV-1 capsid inhibitor, lenacapavir, has achieved its primary endpoint in a phase 2/3 CAPELLA trial.

Phase 2 results include a large cohort of seniors in the study.